

ELEVATOR PITCH

VIRTULEAP COMBINES NEUROSCIENCE AND VIRTUAL REALITY TO DIAGNOSE AND DELAY COGNITIVE DISORDERS, AND ENHANCE COGNITIVE PERFORMANCE.

The company's library of VR games are designed by neuroscientists as translations of standardized neuropsychological assessment tools into 3D rendered environments that test and train a range of cognitive abilities, and generate an order of magnitude more data than any other digital solution.

MARKET OPPORTUNITY

- Over **\$1 trillion** market in terms of the cost cognitive disorders have on the global economy. One-third is incurred by the US economy alone.
- 419.1 million** individuals with cognitive disorders around the world, of which **75.4 million** have the financial ability and willingness to pay.

SERIES-A (FALL 2022)

\$20MILLION

USE OF PROCEEDS



KEY PARTNERS

AARP®

UCSF
University of California
San Francisco

PACIFIC
BRAIN HEALTH
CENTER™

TMC | TEXAS
MEDICAL
CENTER

iHome Lab
HOCHSCHULE
LUZERN

Vall d'Hebron
Hospital

National Innovation
Centre for Ageing

eit Health

dm ac
MEDICAL VALLEY
DIGITAL HEALTH
APPLICATION CENTER

CENTER for
BRAINHEALTH
BRAIN PERFORMANCE INSTITUTE

BRAIN HEALTH & RESEARCH
INSTITUTE

INSURTECH
HUB MUNICH

PROBLEM

Cognitive disorders like Alzheimer's disease have a high cost on quality of life as well as to the economy, and with no solution other than drugs designed to only manage the symptoms, even though there are hundreds of neuroscience-based drugs currently stuck in the approval process because current validation tools and methods are either too slow or too ineffective.

SOLUTION

VR is the first digital format to trigger the autonomic nervous system into believing the experience is real, which means it is not only a cognitive experience, but also an emotional and experiential one. The volumetric datasets are a combination of granular player interaction with rich full body sensory data that is impossible to capture with screen-based formats that exclude the body.

GO-TO-MARKET

The beachhead market is to license the solution to pharma companies as a companion diagnostic that accelerates neuroscience drugs through the approval process by better profiling and predicting the patient segments that have the best possible treatment outcomes. Later clinical validation will allow for approval as a reimbursable digital therapeutic that expands into the wellness, productivity, and education sectors.

MILESTONES

Q3 2022

Assessment module
release

2024

EU regulatory
approval

2023

Digital health
biomarker

2025

FDA regulatory
approval

TECHNOLOGY

Virtuleap is built with the highest standards of software development as the forefront of its technology, utilizing AWS services, building a robust and HIPAA compliant software that can gather and process hundreds of thousands of gameplay and device based data points every second.

MANAGEMENT



Amir Bozorgzadeh
CEO & Cofounder



Hossein Jalali
CTO & Cofounder



Victòria Brugada
Lead Neuroscientist



Nelson Dellis
Chief Product Officer